The goal of this randomized controlled study is to assess the clinical performance and safety of Hedia Diabetes Assistant in adults with type 1 diabetes and suboptimal glycemic control in France. The main question to answer is: \- Does Hedia Diabetes Assistant improve glycemic control? Researchers will compare Hedia Diabetes Assistant in addition to standard treatment to standard treatment alone to see if Hedia Diabetes Assistant can improve glycemic control. Subjects will: * Use Hedia Diabetes Assistant in addition to their standard treatment or only use standard treatment for 6 months. * Visit the clinic once when they are included into the study and will otherwise be followed remotely. * Fill out questionnaires when they are included and after 6 months.
This randomized controlled trial will enroll 154 adults with type 1 diabetes who have suboptimal glycemic control and are treated with multiple daily injections (MDI) of insulin using a pen-based basal-bolus regimen. Subjects must be using a continuous glucose monitor (CGM) as part of their standard care and be telemonitored. The study will be conducted at multiple centres in France, with each subject followed for a total duration of six months. During this period, they will have one in-person visit and two follow-up assessments conducted via phone. Data will be collected through the telemonitoring platform. Subjects will be randomly assigned to either the intervention or control group. The intervention group will use the Hedia Diabetes Assistant in addition to their standard treatment for six months, while the control group will continue with their standard treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
154
Hedia Diabetes Assistant is an insulin bolus calculator app designed to calculate an insulin bolus dose recommendation for people with type 1 or type 2 diabetes on rapid-acting insulin treatment.
Centre Hospitalier Universitaire d'Angers
Angers, France
Hospices Civils de Lyon
Lyon, France
Centre hospitalier universitaire de Nantes
Nantes, France
Centre hospitalier universitaire de Nîmes
Nîmes, France
Hôpital Bichat - Claude-Bernard
Paris, France
Centre hospitalier universitaire de Poitiers
Poitiers, France
Time in range
Glucose between 3.9 and 10 mmol/L (70 to 180 mg/dL)
Time frame: From 14 days before enrollment to the end of treatment at 26 weeks
Time above range
Glucose \> 10.0 mmol/L (\> 180 mg/dL)
Time frame: From 14 days before enrollment to the end of treatment at 26 weeks
HbA1c
Time frame: From enrollment to the end of treatment at 26 weeks
Mean sensor glucose
Time frame: From 14 days before enrollment to the end of treatment at 26 weeks
Glucose Management Indicator (GMI)
Time frame: From 14 days before enrollment to the end of treatment at 26 weeks
Coefficient of Variation (CV)
Time frame: From 14 days before enrollment to the end of treatment at 26 weeks
SD of mean glucose
Time frame: From 14 days before enrollment to the end of treatment at 26 weeks
Time below range
Glucose \< 3.9 mmol/L (\< 70 mg/dL)
Time frame: From 14 days before enrollment to the end of treatment at 26 weeks
Diabetes Treatment Satisfaction
Diabetes Treatment Satisfaction is measured by the Diabetes Treatment Satisfaction Questionnaire
Time frame: From enrollment to the end of treatment at 26 weeks
WHOQoL-BREF
Quality of life is measured by the WHOQoL-BREF questionnaire.
Time frame: From enrollment to the end of treatment at 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.